Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations

Through Positive Action, ViiV Healthcare has committed to invest £2 million per year to encourage MSM and transgender community-led interventions to reduce stigma and discrimination based on sexual orientation, gender identity/expression and/or HIV status. The first phase of the new programme will cover a period of two years.

Published
7 hours ago
From
Viiv Healthcare press release
Bristol-Myers Squibb Co. Is Back in the Hepatitis C Race

Bristol-Myers Squibb took an intriguing approach to developing its hepatitis C drug, daclatasvir. Rather than focus its trials on the United States, the globe's biggest market for spending on medicine, it concentrated trials on Japan. That move allowed daclatasvir to carve out an early lead in Japan, but it also left investors wondering what the company's strategy for the drug in the United States would be -- particularly after the FDA balked at an initial application to approve the drug last fall. This week, Bristol-Myers shed some light on its strategy by announcing that it's resubmitting daclatasvir for approval in the U.S. as an adjunct treatment to be used alongside Gilead Sciences' (NASDAQ: GILD ) top-selling HCV drug Sovaldi in genotype 3 patients.

Published
18 March 2015
From
Motley Fool
Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia

Sangamo's purportedly ground-breaking results in HIV with SB-728 do not stand up under close examination. SB-728 has not shown any indication that it can provide a "functional cure" for HIV, does not compare well to today's standard of care, and cannot find a partner. Sangamo refuses to conduct studies that rigorously assess whether their drugs work. This includes the inclusion of a control arm so assiduously avoided by Sangamo's management.

Published
10 March 2015
From
Seeking Alpha
Here Is Why Gilead Sciences, Inc. Is Still Doing Better Than AbbVie Inc

Based on the prescription data released by Symphony Health, the latest Bloomberg Intelligence (BI) analysis suggests that 95% of hepatitis C patients in the US are being administered with Gilead’s drugs, Harvoni and Sovaldi. On the other hand, AbbVie’s competing drug, Viekira Pak is only covering the remaining 4%.

Published
10 March 2015
From
Bidness
$10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh

Incepta Pharmaceuticals Ltd. doesn’t have a license from Gilead and its version was launched last month, said Managing Director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of Southeast Asia and Africa.

Published
09 March 2015
From
Bloomberg
EECA CAB positions in regards to Janssen, BMS, Gilead and ViiV policy

EECA CAB (Community Advisory Board in Eastern Europe and Central Asia) has published its positions in regards to Janssen, BMS, ViiV and Gilead policy. The positions were developed on the results of the meetings with the companies during last year.

Published
09 March 2015
From
EATG
Natco Pharma ties up with Gilead on hepatitis C drugs

Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.

Published
04 March 2015
From
Reuters
PrEP Access For HIV Prevention In Australia A Step Closer As Gilead Applies To TGA

US pharmaceutical giant Gilead Sciences has begun the application process to have Truvada approved for PrEP in Australia, removing one of the most significant hurdles currently preventing access to the HIV-prevention drug and opening the door to affordable access.

Published
03 March 2015
From
Star Observer
Gilead avoids billions in U.S. taxes on its $1,000-a-pill drug

Gilead Sciences Inc., whose $1,000-a-pill hepatitis C treatment is one of the world's most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas.

Published
27 February 2015
From
Chicago Tribune
HIV and LGTB NGOs and other concerned actors across Europe call for futher action on pre-exposure prophylaxis

The European AIDS Treatment Group (EATG), Europe’s network of HIV activists, and  AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV LGBT civil society organisations and concerned actors, issued an urgent HIV Prevention Manifesto today. We demand that pre-exposure prophylaxis for HIV (PrEP) is made available as soon as possible within the European Union, and that Gilead, the company that makes the PrEP medicine Truvada®, submits an application to the European Medicines Agency (EMA) for a change of indication so that its use to prevent HIV can be approved.

Published
25 February 2015
From
EATG
← First12345...75Next →

Filter by country